Citra-Lock™ 4%

Improves catheter patency

Citra-Lock 4% is recommended in the European Renal Best Practice Guidelines (ERBP) and the American Society of Diagnostic and Interventional Nephrology (ASDIN).

Citra locks have been extensively studied.
4% offers the best benefit/risk ratio.

Citra-Lock is effective in maintaining catheter patency.

Trisodium Citrate 4% (TSC) works as an anti-coagulant and decreases the incidence of infection.

Clinical advantage of Citra-Lock 4% (compared to heparine)

  • safe
  • avoids heparin-associated bleeding
  • improves reliability of INR assyas (prothrombin time – time/international normalised ratio)
  • safe for heparin induced thrombocytopenia (HIT patients)
  • no side effects
  • reduction of tPA use
  • better outcomes over catheter exchange
  • reduction of hospitalisation
  • cost efficient

Increase Safety & Simplified handling

The Citra-Lock vial features a drip free Luer-Slip/Luer-Lock connector

  • preventing microbial contamination
  • protecting against needle stick injuries
  • reducing handling steps
  • promoting intuitive handing

Citra-Lock™ 4% 5ml vial
Boxes contain 20 x 5ml vials
Art. nr. :24060201


Citra-Lock superior to taurolock

More efficient than Taurolidine-based Locking Solutions to prevent Thrombotic Dysfunction of Tunnelled Hemodialyse Catheters: a Retrospective Cohort Study.

Always Innovating

We are an independent company, with more than three decades of experience in marketing healthcare products.
With its roots in haemodialysis, Dirinco has become an expert in extracorporeal circulation treatment of renal failure and catheter lock solutions.